5,602€
0,47%
Echtzeit-Aktienkurs Bausch Health Companies
Bid:
Ask:
Echtzeit-Chart der Bausch Health Companies Aktie
Börsenkurse Bausch Health Companies
USA | - | - | - | - | 6,210$ | 0,32% |
Lang & Schwarz | - | - | - | - | 5,600€ | 0,54% |
Börse Stuttgart | - | - | - | - | 5,601€ | 1,60% |
New York | - | - | - | - | 6,220$ | 0,48% |
Börse Frankfurt | - | - | - | - | 5,615€ | 1,31% |
gettex | - | - | - | - | 5,610€ | 0,57% |
Echtzeit Euro | - | - | - | - | 5,602€ | 0,47% |
Echtzeit USD | - | - | - | - | 6,237$ | 0,77% |
Tradegate | - | - | - | - | 5,614€ | 0,68% |
Fundamentaldaten der Bausch Health Companies Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
---|---|---|---|---|---|---|---|
2023 [CAD] | 11,82 Mrd. | -526,38 Mio. | -799,01 Mio. | -2,19 | - | - | 0,17 |
2022 [CAD] | 10,58 Mrd. | -167,94 Mio. | -292,92 Mio. | -0,81 | - | - | 0,19 |
2021 [CAD] | 10,57 Mrd. | -1,28 Mrd. | -1,19 Mrd. | -3,31 | - | - | 0,19 |
2020 [CAD] | 10,77 Mrd. | -1,25 Mrd. | -751,13 Mio. | -2,12 | - | - | 0,18 |
2019 [CAD] | 11,41 Mrd. | -2,44 Mrd. | -2,37 Mrd. | -6,74 | - | - | 0,17 |
2018 [CAD] | 10,86 Mrd. | -5,38 Mrd. | -5,38 Mrd. | -15,30 | - | - | 0,18 |
2017 [CAD] | 11,32 Mrd. | -2,26 Mrd. | 3,12 Mrd. | 8,90 | - | 0,63 | 0,17 |
2016 [CAD] | 12,82 Mrd. | -3,23 Mrd. | -3,19 Mrd. | -9,20 | - | - | 0,15 |
2015 [CAD] | 13,37 Mrd. | -198,69 Mio. | -373,19 Mio. | -1,09 | - | - | 0,14 |
2014 [CAD] | 9,13 Mrd. | 1,21 Mrd. | 1,01 Mrd. | 3,00 | - | 1,86 | 0,21 |
Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Bausch Health Companies Aktie
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sal